伊维菌素(Ivermectin) - 药物靶点：GluCls_在研适应症：玫瑰痤疮，虱病，疥疮_专利_临床

概要

基本信息

简介伊维菌素是一种小分子药物，作为谷氨酸门控氯离子通道的调节剂起作用，这一作用构成了其药理活性的基础。该药物于 1996 年 11 月获得 FDA 批准，其开发可归功于 Merck Sharp & Dohme Corp 的卓越努力。在众多治疗应用中，Ivermectin 用于治疗寄生虫感染，包括疥疮、虱子感染、丝虫象皮病和不同类型的蠕虫病。此外，它已证明在治疗红斑痤疮方面具有疗效，红斑痤疮是一种以炎症为特征的令人不安的皮肤病症。伊维菌素的广谱抗寄生虫作用使其成为旨在控制和消除高流行地区寄生虫感染的大规模药物管理计划的优秀候选者。

药物类型

小分子化药

别名

mdc-STM

+ [13]

靶点

GluCls

作用机制

谷氨酸门控氯离子通道调节剂

治疗领域

感染血液及淋巴系统疾病皮肤和肌肉骨骼疾病+ [2]

在研适应症

玫瑰痤疮虱病疥疮+ [9]

非在研适应症

寻常痤疮特应性皮炎头虱

原研机构

Merck Sharp & Dohme Corp.

在研机构

浙江海正药业股份有限公司

Merck Sharp & Dohme Corp.

MedinCell SA

+ [7]

非在研机构

Galderma Holding SAGalderma Research & Development SNCTaro Pharmaceuticals U.S.A., Inc.

最高研发阶段批准上市

首次获批日期

美国 (1996-11-22),

盘尾丝虫病类圆线虫病

最高研发阶段(中国)批准上市

特殊审评孤儿药 (日本)

登录后查看时间轴

结构/序列

分子式C47H72O14

InChIKeyVARHUCVRRNANBD-PVVXTEPVSA-N

CAS号70209-81-3

关联

296

项与伊维菌素相关的临床试验

NCT03553615

/ Withdrawn临床2期IIT

Open-label Pilot Clinical Trial of Oral Ivermectin to Treat Atopic Dermatitis

This pilot trial studies how well a novel oral therapeutic agent performs to treat patients with atopic dermatitis, particularly facial dermatitis.

开始日期2030-12-01

申办/合作机构

Stanford University

CTIS2023-505897-13-00

/ Recruiting临床3期

Double-blind, randomised clinical study comparing efficacy and safety of Ivermectin 10 mg/g Cream (Test) vs. Soolantra® 10 mg/g Cream (Reference) vs. Vehicle in patients with papulopustular rosacea - 23-03/Iver-C

开始日期2024-12-06

申办/合作机构

Dermapharm AG

NCT06404333

/ Not yet recruiting临床2期IIT

A Randomized Trial to Assess the Safety, Pharmacokinetics, Acceptability, and Efficacy of Pediatric Oral Ivermectin in Scabies Infected Children Weighing 5 to Less Than 15 Kilograms

The EPIC-15 trial will evaluate the safety, pharmacokinetics, acceptability, and efficacy of pediatric ivermectin (CHILD-IVITAB) in scabies infected children weighing 5 to less than 15 kg. This trial will support future efforts to expand the indication of ivermectin treatment to infants weighing 5 to less than 15 kg to treat numerous NTDs, allowing this young age group equitable access to the numerous benefits of pediatric ivermectin therapy

开始日期2024-10-01

申办/合作机构

University of Oxford

[+2]

100 项与伊维菌素相关的临床结果

登录后查看更多信息

100 项与伊维菌素相关的转化医学

登录后查看更多信息

100 项与伊维菌素相关的专利（医药）

登录后查看更多信息

7,892

项与伊维菌素相关的文献（医药）

2025-06-01·One Health

Treatment of cattle with ivermectin and its effect on dung degradation and larval abundance in a tropical savanna setting

Article

作者: Ruhinda, Miriam ; Brewster, Carlyle ; Meza, Felician ; Lyimo, Issa N ; Xia, Kang ; Shija, Gerald ; Chaccour, Carlos ; Rabinovich, N Regina ; Rist, Cassidy ; Schürch, Roger

When ingested as part of a blood meal, the antiparasitic drug ivermectin kills mosquitoes, making it a candidate for mass drug administration (MDA) in humans and livestock to reduce malaria transmission. When administered to livestock, most ivermectin is excreted unmetabolized in the dung within 5 days post administration. Presence of ivermectin, has been shown to adversely affect dung colonizers and dung degradation in temperate settings; however, those findings may not apply to, tropical environment, where ivermectin MDA against malaria would occur. Here we report results of a randomized field experiment conducted with dung from ivermectin-treated and control cattle to determine the effect of ivermectin on dung degradation in tropical Tanzania. For intact pats, we measured termite colonization, larval numbers and pat wet and dry weights. Pat organic matter was interpolated from a subsample of the pat (10 g wet weight). Additionally, we counted larvae growing in the treated and untreated pats in a semi-field setting. We found that termites colonized ivermectin pats more readily than controls. Despite this, wet weight decreased significantly slower in the ivermectin-treated pats in the first two weeks. As water was lost, sub-sample dry weight increased, and organic matter decreased similarly over time for the treatment and control. Interpolated for whole pats, total organic matter was higher, and larval counts were lower in the ivermectin-treated pats after the first month. Our results demonstrate an effect of ivermectin and its metabolites on dung degradation and fauna in a tropical savanna setting. Because slow dung degradation and low insect abundance negatively impact pastureland, these non-target, environmental effects must be further investigated within the context of real-world implementation of ivermectin MDA in cattle and weighed against the potential benefits for malaria control.

2025-02-01·Research in Veterinary Science

Effect of the sarcoptic mange upon metabolome profiling in wild boars

Article

作者: Balestrieri, Anna ; Vitiello, Chiara ; Gelzo, Monica ; Piscopo, Nadia ; Napolitano, Francesco ; Sacchettino, Luigi ; Esposito, Luigi ; Costanzo, Michele

Sarcoptic mange is a highly contagious disease and represents one of the main health concerns for humans and non-human mammals worldwide. It is caused by the mite Sarcoptes scabiei and can course with different morphological and physiological presentations. Accordingly, aside from skin inflammation, hosts may experience changes in body condition, immune system, biochemistry, reproduction, and thermoregulation, although the understanding of the downstream metabolic burden is still missing. In this context, mange-derived fat store depletion and following imbalance of fatty acid composition might contribute to the severity of the illness. The lack of a tool for early detection of this etiological agent often results in significant financial losses for farmers and harm to animal welfare. Therefore, using targeted LC-MS/MS-based metabolomics approach, we sought to investigate the impact of sarcoptic mange upon metabolome profiling in the blood serum of mangy wild boars. Thirteen wild boars were analyzed in three different clinical conditions, namely when they were sick, during the therapeutic treatment with ivermectin, and when they were deemed recovered from the disease. We identified specific long-chain acylcarnitines highly abundant in the blood serum of the subjects within the infection phase, when compared to the ivermectin-treated and healthy conditions. Overall, data from our preliminary study highlighted the need for more accurate and broad-based studies, about the potential role of the long chain acylcarnitines in the metabolic homeostasis, to help early diagnose of the sarcoptic mange.

2025-02-01·Acta Parasitologica

Study of the Drug Resistance Function of Ivermectin-Resistance-Related miRNAs in Haemonchus contortus

Article

作者: Yang, Lin ; Zhang, YanMin ; Liu, ChunXia ; Wen, HaiFeng ; Wang, WenLong

Haemonchus contortus has caused significant economic losses in many regions. The emergence of drug resistance has created new difficulties for the prevention and control of parasitic diseases in cattle and sheep. The mechanism of drug resistance to ivermectin in H. contortus is not clear; therefore, it is of great significance to study it. Non-coding RNAs, especially microRNAs (miRNAs), play important roles in drug resistance in some human tumors and insects. However, few studies have investigated whether miRNAs are involved in the regulation of drug resistance to ivermectin. In the early stages of this study, four miRNAs that may be involved in the regulation of ivermectin resistance in H. contortus were identified by high-throughput sequencing analysis of ivermectin-sensitive and -resistant strains of H. contortus. To verify whether these miRNAs are indeed related to ivermectin resistance in H. contortus, RNA interference (RNAi) experiments were performed on these miRNAs. The expression of candidate drug-resistance-related miRNA target genes before and after RNAi was detected by quantitative polymerase chain reaction. The resistance of the third-stage larvae (L3s) of H. contortus before and after RNAi was detected using 0.5% dimethyl sulfoxide and 100 µg/mL ivermectin treatment. The locomotion behavior of the L3s of H. contortus before and after RNAi was detected by counting the frequency of head thrashes and body bending. Finally, we confirmed that miR-10,025-y, miR-5960-z, miR-27-y, and miR-276-y were involved in and regulate ivermectin resistance in H. contortus.

110

项与伊维菌素相关的新闻（医药）

2025-01-16

·PRNewswire

Frontline COVID Docs (FLCCC) Gear Up for Kennedy Confirmation Battle; Announce New Name & Expanded Focus

"For many of us, COVID was an eye-opener. The shameful censorship of discussion and debate among accomplished doctors by America's healthcare agencies cost many lives. This must never happen again." – Dr. Joseph Varon WASHINGTON, Jan. 16, 2025 /PRNewswire/ -- The Frontline COVID-19 Critical Care Alliance (FLCCC) announced today that the group is changing its name to the Independent Medical Alliance (IMA) as the nation prepares for the coming Kennedy nomination debates. "We're about to have an unprecedented national discussion about America's broken healthcare system," said Dr. Joseph Varon, President and Chief Medical Officer of the Independent Medical Alliance. "For many of us, COVID was an eye-opener. I was on the front lines fighting to save lives. The shameful censorship of discussion and debate among accomplished doctors by America's healthcare agencies cost many lives. This must never happen again." Representing over 15,000 doctors and other medical professionals, the FLCCC vaulted to national prominence by pushing back against vaccine mandates and other government induced COVID policy failures, while also advocating for early and cost-effective alternative treatments, including ivermectin, which has proven to be highly effective against COVID. "They demonized accomplished virologists and others who knew that ivermectin was saving lives," continued Varon. "Hundreds of thousands died due to the censorship of debate. At our hospital, we considered alternatives, and our published mortality rate was 4.4% while major hospitals at the time were experiencing 23% to 26% rates of ICU death." "Our success raised interest among those at FDA and CDC, but not the way one would expect. They sent scores of briefcase wielding bureaucrats to try and shut down our treatment programs. We were outside of the PhRMA profit orthodoxy. We were non-conformists. And although we were saving more lives, that didn't appear to be the priority." "The Kennedy confirmations will be about restoring health to America's healthcare systems, and we're looking forward to that discussion," concluded Varon. About the IMA (Formerly FLCCC Alliance) The Independent Medical Alliance™ is a nonprofit, 501(c)(3) organization and coalition of physicians, nurses, and healthcare professionals united by a mission to restore trust and transparency in healthcare. The organization's mission is one driven by Honest Medicine™ that prioritizes patients above profits and emphasizes long-term wellness and disease prevention through empowerment of both physicians and their patients. With a focus on evidence-based medicine, informed consent, and systemic reform, IMA is driving a movement to create a more compassionate and effective healthcare system. For more information about the Independent Medical Alliance, visit Contact Lynne Kristensen Independent Medical Alliance [email protected] (202) 987-5655 SOURCE Independent Medical Alliance WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

AHA会议

2024-11-26

·Business Wire

Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch of Ivermectin Tablets USP, 3 mg in US Market

HYDERABAD, India--( BUSINESS WIRE )--Dr. Reddy's Laboratories, Inc. and Senores Pharmaceuticals, Inc. today announced the launch of Ivermectin Tablets USP, 3 mg, which is bioequivalent and therapeutically equivalent to STROMECTOL® Tablets of Merck Sharp and Dohme LLC in the U.S. market. The product will be marketed by Dr. Reddy's. “We are pleased to advance our growth with the launch of a limited-competition product. With our continuous focus on niche opportunities, we are proud to be the second generic to receive approval for this product,” stated Swapnil Shah, Managing Director, Senores Pharmaceuticals Limited. Ivermectin Tablets, 3 mg brand and generic products, had U.S. sales of approximately $20 million MAT for the twelve months ending in September 2024 according to IQVIA. RDY-1124-747 About Dr. Reddy’s : Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of ‘Good Health Can’t Wait’, we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com . About Senores Pharmaceuticals, Inc. : Senores Pharmaceuticals, Inc., based in Georgia, USA, is a wholly owned subsidiary of Senores Pharmaceuticals Limited and one of the fastest-growing pharmaceutical companies in the USA. The company has more than 25 products commercially launched or filed with the USFDA. For more information about Senores Pharmaceuticals, Inc., please visit www.senorespharma.com . Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers’, products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report on Form 20-F for the year ended March 31, 2022. The company assumes no obligation to update any information contained herein.

上市批准

2024-11-16

·知识分子

反疫苗代表被提名下一任美国卫生部长

11.16 知识分子 The Intellectual 2024年8月23日，肯尼迪在亚利桑那州的一场选举前的集会上支持特朗普，为特朗普背书。图源：维基百科 2024年11月14日，特朗普宣布提名小肯尼迪为新的卫生与公众服务部（HHS）部长。小肯尼迪是著名的反疫苗人士，发表过大量反智反科学言论。他被提名HHS部长，不仅代表了相对特朗普1.0，特朗普2.0在美国医疗、健康政策上的重大转向，也是对科学界、医学界的重大威胁。说这是美国健康领域的至暗一刻并不为过。撰文 | 周叶斌 ● 　● 　● 01 反疫苗阴谋论者被提名NHS部长小肯尼迪，全名Robert F. Kennedy Jr，美国媒体有时候就叫他RFK Jr，美国前司法部长罗伯特·肯尼迪之子。小肯尼迪出生于1954年，9岁时叔叔肯尼迪总统遇刺身亡，14岁时，父亲，当时的纽约州参议员罗伯特·肯尼迪遇刺身亡。由于经历了多起家庭悲剧，小肯尼迪很小就通过滥用药物寻求解脱，16岁因携带大麻被捕，先后被两所寄宿学校开除。后来小肯尼迪延续叔叔与父亲的脚步，进入哈佛读法律，但在那个时候也是吸毒，被同学称为毒贩。 1982年，年仅28岁的肯尼迪就任曼哈顿的助理检察长，但仅一年，因为没有通过律师资格考试，不得不辞职。1983年，小肯尼迪还因携带海洛因被捕，并被判了两年的缓刑与社区服务。这次判刑却改变了小肯尼迪的一生。一方面缓刑要求他接受戒毒治疗，据他说，这让他结束了长达14年的海洛因滥用。另外，更重要的是，他到自然资源保护协会（Natural Resources Defense Council）做志愿者，让他接触到了环保，可以说找到了人生追求。后来他到致力于改善纽约著名河流哈德逊河的环保组织Riverkeeper做志愿者，成为该组织的律师。他的一系列诉讼，对哈德逊河的环境改善乃至树立美国对水域环境治理的标准，都有着重要作用。为此，小肯尼迪曾经是08年奥巴马政府的环保署署长候选人之一。非常遗憾的是，2010年以后，小肯尼迪逐渐由环保战士蜕变成了反疫苗运动代言人。2015年，他加入了反疫苗组织Children's Health Defense。这个组织前身叫World Mercury Project，因为部分疫苗里使用的少量硫柳汞防腐剂，宣称疫苗对儿童有害。实际上科学研究都证明了微量的硫柳汞不会对健康产生威胁。小肯尼迪后来成了Children's Health Defense的主席。新冠疫情期间，小肯尼迪带着Children's Health Defense飞速发展，成了主要的反疫苗声音，大量散布疫苗导致自闭症，氯喹、伊维菌素可以治疗新冠等不实信息。可以看到，小肯尼迪不仅没有医学背景，而且长期散播不实信息、阴谋论，这样的人被提名HHS部长，可以说是美国非常荒唐的一幕。 02 重大转变 2024年总统大选中，小肯尼迪一开始是对拜登发起初选挑战，失败后决定以独立候选人身份参选，但在24年8月他宣布退选并表态支持特朗普，条件就是在未来政府的健康决策里要扮演重要角色。而不同于基本在重复8年前口号的经济、移民等方向，在健康领域，特朗普从竞选时期到胜选后，在多个场合明确表示支持他这次选举的小肯尼迪将扮演重要角色。要让小肯尼迪在健康领域go wild（为所欲为）。小肯尼不仅与当下拜登政府的健康官员们相去甚远，与特朗普1.0时的几位主要健康领域官员也有着完全不同的背景。特朗普首次当选时，HHS部长为Alex Azar，法律背景，在小布什政府时期进入HHS，在小布什连任后成为HHS副部长。07年辞去HHS职务后任职制药巨头礼来十年。当时的两任FDA局长，分别为Scott Gottlieb（2017-2019）与Stephen Hahn（2019-2021），Gottlieb辞任后，时任NCI主任Norman Sharpless曾短暂代理FDA局长。Gottlieb在成为FDA局长前，做过临床医生，在FDA与CMS（联邦医疗保险与联邦医疗辅助计划服务中心）任职过，后进入医疗投资。Stephen Hahn则是著名的放射科医生，成为FDA局长前为MD Anderson的首席医学官。CDC主任Redfield，研究HIV病毒出身。从上述特朗普首次执政时与医药行业相关的政务官背景来看，当时极为反传统的特朗普，选择的健康领域官员却极为传统。考虑到新冠疫情中，特朗普与当时传统医学科学出身的FDA局长Stephen Hahn、NIAID主任Fauci产生严重矛盾，特朗普在2.0版政府里靠近小肯尼迪的医学观点并不令人意外。相对这些传统科学背景或者至少不反科学的官员，小肯尼迪被提名HHS部长代表了特朗普2.0政府在健康尤其是公卫方面与1.0时比，发生了重大转向。这种转向可能给美国公众带来最直接的健康威胁。毕竟四年多前，正是这些传统的健康官员坚持科学原则，才让FDA、CDC等机构维持了按科学证据做推荐，没有让尘嚣甚上的反疫苗阴谋论、氯喹伊维菌素能治疗新冠等伪科学造成更大危害。 03 小肯尼迪就任NHS部长带来多重威胁 HHS，美国的卫生与公众服务部，是所有美国政府部门里预算总最大的部门之一，2025财年HHS的可自由支配开支预算高达1300亿美元，仅次于国防部。 HHS有那么高的预算，很重要的原因是它下面有多个与民众健康密切相关的机构，像FDA，CDC都是HHS下旗下。HHS部长无疑是健康领域的要职，而小肯尼迪担任这个职位，也会带来多重威胁。首先，美国监管药品与食品的部门，FDA，是归HHS管辖。而FDA的职责包括批准、审核药品，监管市场上的保健品、食品安全，每一项都与民众健康息息相关。HHS部长的位置让小肯尼迪有机会干预FDA的工作。而小肯尼迪还明确表达这种干涉倾向，他曾在采访中表示要消除FDA的整个营养部门。目前FDA审批新药上市的经费大多来自药企申请药品上市的注册费，独立于政府预算。这种注册费制度保证了FDA有足够的人手，可以及时完成复杂的药品监管审理。可小肯尼迪却表示要取消注册费制度，若得以实行，可能严重拖延新药上市的速度，威胁患者利益。其次，CDC隶属于HHS。作为最重要的公卫部门，CDC的ACIP（免疫规划委员会）负责疫苗的推荐。而只要是ACIP推荐的疫苗，美国的医保基本都会覆盖。而CDC也是目前最需要担心的，因为ACIP的委员由HHS部长任命。反疫苗的小肯尼迪一旦掌管HHS，完全可以通过任命与他想法类似的人进入ACIP，严重威胁美国的免疫规划。小肯尼迪最近还表示要从饮用水中清除氟。在饮用水中加入少量氟，大幅降低了蛀牙率，被认为是美国历史上最突出的公卫成果之一。小肯尼迪却错误地宣称添加氟导致癌症，威胁孩童智力水平。实际上，美国饮用水普遍添加的氟剂量极低，完全在包括WHO在内各健康机构认定的安全范围内。从反对添加氟，也能看出小肯尼迪可能会推行反公共健康科学共识的政策，危害民众健康。再次，全球最重要的生命科学研究机构，美国国立卫生研究院NIH，也在HHS旗下。小肯尼迪已经宣称要开掉600名NIH员工。很多最新的药物、治疗方法，表面上看是某某药企做出来的，但追本溯源，大多有NIH的基础研究的影子，甚至在后期研发里也离不开NIH的协助。像是新冠疫情期间起到关键保护作用的两个mRNA疫苗中，Moderna的新冠疫苗整个研发过程都获得了NIH的大力支持。过去，NIH的工作基本不受到美国政坛变化的干预。小肯尼迪若是打破该传统，对全球健康领域都是严重隐患。 04 小肯尼迪广泛的反科学反智思想真正让小肯尼迪担任HHS部长这一要职异常危险的，是他长期的反科学反智倾向，参考他10月25日在社交网络上发的贴子：该帖子中，小肯尼宣称FDA对公共健康的压迫即将结束，包括那些对致幻剂、多肽、干细胞、生牛奶、高压治疗、螯合物、伊维菌素、氯喹等这一系列有益健康的东西的打压。伊维菌素、氯喹是重复新冠疫情期间这两个药物有治疗新冠作用的不实信息。他说的多肽、干细胞也不是指正经的获批药物，而是类似打干细胞、胶原蛋白有抗衰老功效等虚假宣传。可以看出小肯尼对药物的看法并不基于科学，受很多类似顺势疗法等伪科学的影响。颇为讽刺的是，2017年，特朗普1.0时期的FDA局长Scott Gottlieb提出加强针对顺势治疗药物的监管，FDA也发出多封警告函，要求一些不安全的顺势疗法下市。如今很可能出现完全相反的局面。大量打着天然、自然的假药不必担心监管部门的审视。这在小肯尼迪等人看来可能是让美国再次健康，但其实是让美国生病。食品领域，虽然RFK提倡健康饮食这些不违反科学的原则，但在具体方案、办法上，他往往会陷入反智圈套。像他提到的生牛奶就很能反映一个思维模式，所谓天然就是好。生牛奶是指未经巴氏消毒的牛奶，一些人认为生牛奶有特殊的营养。但这并不符合事实。实际上，牛奶很容易被细菌污染，未经巴氏消毒的生牛奶蕴藏着巨大的安全隐患。根据CDC统计，1998到2018年间，美国发生了202起生牛奶导致的疾病暴发，而这还只是上报的数据，存在低估，因为大部分相关食物中毒根本不会报告到CDC。此外，小肯尼迪还说过无线网络导致癌症，艾滋病不是HIV感染引发等各种反科学言论。显然，小肯尼迪的健康观点，以及他和特朗普鼓吹的让美国再次健康（make America healthy again），建立在大量的不实信息之上，一旦变成政府决策，危害无穷。在所有反科学反智言论中，小肯尼迪最持之以恒，也最令人担心的无疑是反疫苗。这方面，他甚至可以说是双手沾满了鲜血。 2019年，人口仅20万的太平洋岛国萨摩亚暴发麻疹，造成5700例疾病，83人死亡。当时萨摩亚6-11个月的婴儿里20%感染了麻疹，每150名婴儿就有1人死于麻疹。这次麻疹暴发最主要的原因便是当地麻疹疫苗接种率从2017年的74%突然下降到了2018年的34%。为什么接种率会如此下滑？这要追溯到此前当地护士一次操作失误，将麻醉剂误用于稀释疫苗，导致两名孩童不幸身亡。而小肯尼迪为首的反疫苗人士抓住机会，大肆传播疫苗有严重危害，可以致死的虚假信息。这就是小肯尼迪在健康领域go wild（为所欲为）的历史成绩。此前特朗普过渡团队的成员都承认小肯尼迪主管健康领域后，可能将疫苗下架。据称，小肯尼迪说要检验疫苗的数据，只要给他数据，就能证明这些疫苗不安全，制药公司将不得不下架疫苗。可他鼓吹的疫苗导致自闭症早已被科学界证伪。而小肯尼迪此前领导的反疫苗组织Children’s Health Defenses散布过大量虚假信息，还起诉反驳这些不实信息的媒体机构。执掌HHS，拿到疫苗安全性“数据”后，真能指望他会诚实宣布科学界早就知道的事实：上市的疫苗安全性有保障？根据世界卫生组织估计，全球儿童疫苗接种每年避免的死亡在400万以上，而小肯尼迪在2023年还宣称没有一个疫苗是安全的。他领导HHS，将是的公共健康的巨大威胁。 05 小肯尼迪恐怕只是开始小肯尼迪还在帮特朗普筛选健康相关职位的官员候选人简历。物以类聚，人以群分，当小肯尼迪被提名HHS部长时，下一任的FDA局长、CDC主任、NIH主任又会是什么样的人？必须承认，小肯尼迪说的一些原则表面上没有问题，比如中止药品监管机构与制药行业的旋转门，减少对健康有负面作用的深加工食品。这些说法击中了我们对当下健康政策、行业管理的担忧，很有诱惑力。但是解决或改善我们面临的健康挑战需要建立在科学之上，追随小肯尼迪这样的反智反科学思维，只会是缘木求鱼。以药品监管与制药业的旋转门为例。确实有太多FDA高管跳槽企业或与企业交流过度的案例，严重威胁民众对FDA独立性的信任。但是我们也必须看到制药业的复杂性意味着无论是监管部门还是产业界，都需要有综合背景的人才。以特朗普的首位FDA局Gottlieb为例。在他就任前，美国公众的一个普遍担忧是Gottlieb作为风投人与产业界有着极为密切的联系，是否会过度为医药企业站台。可上任后，Gottlieb过去广泛的政府、产业界经验带来了高度合作的管理方式，获得各方认可。他开创了因成瘾风险大而下架阿片药物的先例，推迟新的烟草类产品上市审核并开启对尼古丁含量监管，这些一方面有着政府健康部门出身不畏惧对产业界动手的态度，另一方面也带有产业界敢于使用新办法、定新规矩的特征。我们需要更好的机制来维系FDA等部门的独立性，但我们不需要小肯尼迪那种偏颇、倒退的管理思维。小肯尼迪被提名HHS部长，我们不得不担忧当健康部门的最高级别官员反科学，宣扬阴谋论，普通民众又能从那里获得可靠的健康建议、医学指导？这又怎么可能是让美国健康呢？这其实是美国科学界、医学界黑暗的一刻。参考文献：（上下滑动可浏览） 1.https://www.vox.com/health/385541/rfk-jr-trump-hhs-vaccines-fluoride 2.https://www.reuters.com/world/us/rfk-jr-is-reviewing-resumes-top-trump-health-jobs-sources-say-2024-11-09/ 3.https://endpts.com/biotech-industry-worries-over-potential-for-rfk-jr-ally-as-fda-pick/ 4.https://www-nidcr-nih-gov.libproxy1.nus.edu.sg/health-info/fluoride/the-story-of-fluoridation 5.https://www-nih-gov.libproxy1.nus.edu.sg/news-events/news-releases/statement-nih-barda-fda-emergency-use-authorization-moderna-covid-19-vaccine 亲爱的读者们，不星标《知识分子》公众号，会错过每日科学新知！星标《知识分子》，紧跟前沿科学，一起探索科学的奥秘吧！请戳上图卡片添加星标关注《知识分子》视频号 get更多有趣、有料的科普内容 END

疫苗

100 项与伊维菌素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00804	伊维菌素	D11AX22 P02CF01	DB00602

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
玫瑰痤疮	美国	Galderma Laboratories LP	2014-12-19
虱病	美国	Arbor Pharmaceuticals LLC	2012-02-07
疥疮	日本	MSD KK	2006-08-21
蛔虫病	中国	浙江海正药业股份有限公司	2001-01-01
丝虫性象皮病	中国	浙江海正药业股份有限公司	2001-01-01
蛲虫病	中国	浙江海正药业股份有限公司	2001-01-01
蠕虫病	中国	浙江海正药业股份有限公司	2001-01-01
钩虫感染	中国	浙江海正药业股份有限公司	2001-01-01
鞭虫病	中国	浙江海正药业股份有限公司	2001-01-01
盘尾丝虫病	美国	Merck Sharp & Dohme Corp.	1996-11-22
类圆线虫病	美国	Merck Sharp & Dohme Corp.	1996-11-22

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
玫瑰痤疮	申请上市	欧盟	Adalvo Ltd.	2023-04-18
寻常痤疮	临床前	加拿大	Galderma Holding SA	2016-04-25
寻常痤疮	临床前	加拿大	Galderma Research & Development SNC	2016-04-25
新型冠状病毒感染	药物发现	保加利亚	MedinCell SA	2022-03-25
特应性皮炎	药物发现	加拿大	Galderma Research & Development SNC	2016-11-01
特应性皮炎	药物发现	加拿大	Galderma Holding SA	2016-11-01
寻常痤疮	药物发现	德国	Galderma Research & Development SNC	2016-04-25
寻常痤疮	药物发现	法国	Galderma Research & Development SNC	2016-04-25
寻常痤疮	药物发现	德国	Galderma Holding SA	2016-04-25
寻常痤疮	药物发现	法国	Galderma Holding SA	2016-04-25

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05305560 (SAIVE, CTgov)	临床2期	新型冠状病毒感染	400	Ivermectin Tablets (Active IMP)	構網觸糧鬱觸築獵膚繭(糧衊襯鏇構鑰顧淵糧築) = 鑰觸鏇膚築窪廠鹹憲鹹觸鑰蓋鬱製選膚窪鬱醖 (糧醖窪構遞淵廠蓋艱醖, 廠窪齋構壓鹹觸襯襯齋 ~ 衊糧願夢淵繭艱窪遞構) 更多	-	2024-12-10
				Matching placebo tablets (Placebo)	構網觸糧鬱觸築獵膚繭(糧衊襯鏇構鑰顧淵糧築) = 夢糧夢積壓淵蓋衊蓋鬱觸鑰蓋鬱製選膚窪鬱醖 (糧醖窪構遞淵廠蓋艱醖, 膚壓獵蓋蓋淵醖遞憲蓋 ~ 製齋選範鏇鑰衊壓築艱) 更多
NCT04056325 (StrongMoxi, CTgov)	临床2/3期	类圆线虫病	617	Moxidectin (Phase 2a - Arm A (Moxidectin 2 mg))	齋選顧範齋觸鬱壓鑰獵(淵鹹鹽糧顧廠齋繭顧壓) = 壓鬱積積艱觸獵繭鏇夢膚範憲艱觸繭網膚壓醖 (廠憲艱膚選獵衊壓獵鹽, 顧鏇選窪積簾廠願積夢 ~ 襯憲窪觸觸醖鬱壓鏇憲) 更多	-	2024-12-09
				Moxidectin (Phase 2a - Arm B (Moxidectin 4 mg))	齋選顧範齋觸鬱壓鑰獵(淵鹹鹽糧顧廠齋繭顧壓) = 鏇製艱鏇鹽廠製鏇構艱膚範憲艱觸繭網膚壓醖 (廠憲艱膚選獵衊壓獵鹽, 襯獵獵遞積觸醖艱膚膚 ~ 齋淵獵網鏇襯簾鬱觸窪) 更多
NCT03527732 (CTgov)	临床2/3期	鞭虫病	1,673	Albendazole (Albendazole in Côte d'Ivoire)	襯鹹願襯膚糧膚積壓齋(衊餘壓襯鏇襯鹽構築構) = 衊夢齋齋糧襯膚艱遞鑰鏇繭網窪簾憲膚築衊觸 (獵衊窪獵壓衊壓鏇齋構, 壓獵艱繭糧範觸積顧製 ~ 膚築醖窪積艱齋衊願簾) 更多	-	2024-03-20
				Albendazole+Ivermectin (Albendazole and Ivermectin in Côte d'Ivoire)	襯鹹願襯膚糧膚積壓齋(衊餘壓襯鏇襯鹽構築構) = 襯範淵蓋膚鬱觸壓觸選鏇繭網窪簾憲膚築衊觸 (獵衊窪獵壓衊壓鏇齋構, 構鹹夢顧夢齋遞構膚壓 ~ 壓構鹽鏇鏇顧選鹹觸遞) 更多
NCT04848688 (StrongMoxi_KH, CTgov)	临床3期	类圆线虫病	332	Placebo+Moxidectin 2 mg (Moxidectin)	齋鬱餘顧製願選襯廠鏇(襯壓艱築憲鹹鹹遞網遞) = 蓋簾鏇壓鑰憲範觸願壓餘衊遞製網遞鹽憲願齋 (遞糧願積鏇窪壓製餘選, 壓鹽構醖淵醖糧顧鹹衊 ~ 醖製網憲襯廠廠顧繭膚) 更多	-	2024-01-24
				Placebo+Ivermectin 3 mg (Ivermectin)	齋鬱餘顧製願選襯廠鏇(襯壓艱築憲鹹鹹遞網遞) = 廠鹹網窪顧壓壓餘願繭餘衊遞製網遞鹽憲願齋 (遞糧願積鏇窪壓製餘選, 壓築夢糧鑰襯蓋淵壓艱 ~ 鏇憲齋襯顧壓製簾製廠) 更多
NCT03967054 (RIMDAMAL II, CTgov)	临床3期	疟疾	4,124	Ivermectin (Ivermectin Mass Drug Administration)	網簾蓋願獵膚積醖鑰鏇(構範願築築簾鏇淵選簾) = 醖鬱醖鑰觸艱蓋範選夢遞觸簾願獵淵窪醖廠願 (醖餘艱餘願遞遞膚衊顧, 積製夢觸壓鑰遞願壓鏇 ~ 糧衊齋顧鏇膚壓觸淵顧) 更多	-	2024-01-11
				Placebo oral tablet (Placebo Mass Administration)	網簾蓋願獵膚積醖鑰鏇(構範願築築簾鏇淵選簾) = 蓋顧觸鏇築構積簾鹽餘遞觸簾願獵淵窪醖廠願 (醖餘艱餘願遞遞膚衊顧, 齋夢獵範憲鑰廠齋窪簾 ~ 鏇製襯膚鹹築選範艱選) 更多
NCT05894538 (CTgov)	临床3期	新型冠状病毒感染	1,459	Ivermectin (Arm D - Ivermectin 600)	憲鏇衊襯築構鹽獵築鑰(鬱廠齋餘獵範觸窪淵蓋) = 淵艱膚鏇廠鏇餘構鬱鏇築鏇蓋積廠衊廠壓積夢 (襯襯選繭選齋製願艱積, 衊襯鑰醖衊糧積鑰膚製 ~ 夢蓋憲獵壓糧壓齋觸蓋) 更多	-	2023-09-28
				Placebo (Arm D - Placebo)	憲鏇衊襯築構鹽獵築鑰(鬱廠齋餘獵範觸窪淵蓋) = 獵顧獵糧襯衊獵齋鹽願築鏇蓋積廠衊廠壓積夢 (襯襯選繭選齋製願艱積, 製繭壓壓願製遞願鑰艱 ~ 鹽壓鏇鹹鹽鬱製鬱觸鏇) 更多
NCT04410406 (Pubmed \| PLoS Negl Trop Dis)	临床3期	丝虫性象皮病 Wuchereria bancrofti microfilaremia	-	ivermectin + albendazole	衊齋繭範艱廠遞壓淵築(蓋鹹網餘鹽艱窪選淵構) = Four participants had transient Grade 3 hematuria after treatment (3 after IDA and 1 after IA) 淵獵簾淵醖構襯艱構範 (願顧範鹽製艱選糧膚製 ) 更多	积极	2023-09-18
				moxidectin + albendazole
NCT04510194 (COVID-OUT, CTgov)	临床3期	新型冠状病毒感染	1,323	Metformin (Treatment Arm - Metformin Only Group)	觸餘艱衊鑰簾積製顧顧(繭鹽憲憲餘衊齋願壓餘) = 製簾餘簾獵鹽網鏇壓鬱艱網簾鹽壓鹽鏇獵醖積 (醖範醖鑰齋夢襯願齋夢, 構鑰艱繭簾鏇簾鹹膚範 ~ 壓壓廠襯衊鹽構糧鏇襯) 更多	-	2023-07-13
				Placebo (Treatment Arm - Placebo Group)	觸餘艱衊鑰簾積製顧顧(繭鹽憲憲餘衊齋願壓餘) = 餘鏇觸淵遞構遞廠醖窪艱網簾鹽壓鹽鏇獵醖積 (醖範醖鑰齋夢襯願齋夢, 憲鬱鬱壓願選獵鹽構願 ~ 壓夢醖製衊糧範簾蓋觸) 更多
WCD2023	N/A	疥疮	-	ivermectin (Community residents)	憲獵蓋積觸淵糧網築餘(選壓衊觸蓋醖簾憲糧齋) = 廠壓鏇鑰衊積糧鹽鏇選鹽遞淵積糧獵選鏇積選 (觸觸窪襯築繭構鑰淵醖 )	-	2023-07-06
WCD2023	N/A	玫瑰痤疮	-	Ivermectin 1% cream and doxycycline 40 mg	範顧衊繭築窪糧艱鏇廠(衊餘糧膚鹹簾遞構壓衊) = 範築觸襯蓋醖淵遞願襯蓋鑰憲範廠夢醖築廠糧 (襯齋範餘憲網壓構構製 )	-	2023-07-03
				Ivermectin 1% cream and Placebo	範顧衊繭築窪糧艱鏇廠(衊餘糧膚鹹簾遞構壓衊) = 廠獵範齋艱範築鏇憲選蓋鑰憲範廠夢醖築廠糧 (襯齋範餘憲網壓構構製 )